Journal
BRITISH JOURNAL OF CANCER
Volume 124, Issue 5, Pages 857-859Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-020-01202-y
Keywords
-
Categories
Funding
- MD Anderson Cancer Center support grant [P30 CA016672]
- V Foundation [VC2020001]
Ask authors/readers for more resources
SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies and PARP inhibition, making it a potential biomarker for targeting the DDR.
The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available